Sol-Gel Technologies Income After Taxes 2016-2024 | SLGL
Sol-Gel Technologies income after taxes from 2016 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Sol-Gel Technologies Annual Income After Taxes (Millions of US $) |
2023 |
$-27 |
2022 |
$-15 |
2021 |
$3 |
2020 |
$-29 |
2019 |
$-25 |
2018 |
$-33 |
2017 |
$-32 |
2016 |
$-21 |
2015 |
$-10 |
Sol-Gel Technologies Quarterly Income After Taxes (Millions of US $) |
2024-06-30 |
$2 |
2024-03-31 |
$-6 |
2023-12-31 |
$-5 |
2023-09-30 |
$-6 |
2023-06-30 |
$-6 |
2023-03-31 |
$-11 |
2022-12-31 |
$-6 |
2022-09-30 |
$-3 |
2022-06-30 |
$-0 |
2022-03-31 |
$-6 |
2021-12-31 |
$14 |
2021-09-30 |
$1 |
2021-06-30 |
$-8 |
2021-03-31 |
$-4 |
2020-12-31 |
$-6 |
2020-09-30 |
$-9 |
2020-06-30 |
$-7 |
2020-03-31 |
$-7 |
2019-12-31 |
$-7 |
2019-09-30 |
$-7 |
2019-06-30 |
$-5 |
2019-03-31 |
$-6 |
2018-12-31 |
$-13 |
2018-09-30 |
$-8 |
2018-06-30 |
$-7 |
2018-03-31 |
$-6 |
2017-12-31 |
|
2017-09-30 |
|
2017-06-30 |
$-6 |
2016-12-31 |
|
2015-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.015B |
$0.002B |
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|